Clinical and Translational Medicine (Nov 2021)
An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
- Alison Findlay,
- Craig Turner,
- Heidi Schilter,
- Mandar Deodhar,
- Wenbin Zhou,
- Lara Perryman,
- Jonathan Foot,
- Amna Zahoor,
- Yimin Yao,
- Ross Hamilton,
- Mary Brock,
- Christina Raso,
- Jessica Stolp,
- Marie Galati,
- Dieter Hamprecht,
- Brett Charlton,
- Wolfgang Jarolimek
Affiliations
- Alison Findlay
- Pharmaxis Frenchs Forest New South Wales Australia
- Craig Turner
- Pharmaxis Frenchs Forest New South Wales Australia
- Heidi Schilter
- Pharmaxis Frenchs Forest New South Wales Australia
- Mandar Deodhar
- Pharmaxis Frenchs Forest New South Wales Australia
- Wenbin Zhou
- Pharmaxis Frenchs Forest New South Wales Australia
- Lara Perryman
- Pharmaxis Frenchs Forest New South Wales Australia
- Jonathan Foot
- Pharmaxis Frenchs Forest New South Wales Australia
- Amna Zahoor
- Pharmaxis Frenchs Forest New South Wales Australia
- Yimin Yao
- Pharmaxis Frenchs Forest New South Wales Australia
- Ross Hamilton
- Pharmaxis Frenchs Forest New South Wales Australia
- Mary Brock
- Quanterix Billerica Massachusetts USA
- Christina Raso
- Quanterix Billerica Massachusetts USA
- Jessica Stolp
- Pharmaxis Frenchs Forest New South Wales Australia
- Marie Galati
- Pharmaxis Frenchs Forest New South Wales Australia
- Dieter Hamprecht
- Pharmaxis Frenchs Forest New South Wales Australia
- Brett Charlton
- Pharmaxis Frenchs Forest New South Wales Australia
- Wolfgang Jarolimek
- Pharmaxis Frenchs Forest New South Wales Australia
- DOI
- https://doi.org/10.1002/ctm2.572
- Journal volume & issue
-
Vol. 11,
no. 11
pp. n/a – n/a
Abstract
No abstracts available.
